Full-Time

Bioinformatics Data Engineer

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$120k - $145kAnnually

Mid

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Bioinformatics
Biology & Biotech
Data & Analytics
Required Skills
Python
R
SQL
Linux/Unix
Data Analysis
Requirements
  • Master’s or bachelor’s degree with 3+ years’ experience in biology/computer science related field.
  • Expertise using linux clusters, cloud computing and file systems.
  • Proficient in designing and querying databases using SQL and object-relational mapping techniques.
  • Skilled in utilizing Python and R for data manipulation and analysis.
  • Strong familiarity with bioinformatics data types and outputs.
  • Excellent communication skills, enabling effective collaboration and conveying technical information clearly to diverse audiences.
Responsibilities
  • Act as a main liaison between internal scientists and external molecular diagnostic providers.
  • Be the primary point of contact for the data transfer process, establishing connections between our cloud storage and external file shares.
  • Help develop scripts and processes to clean, upload and accession biomarker data from clinical trails into internal systems for further analysis.
  • Carry out data modeling and curation to ensure data quality and relevance.
  • Collaborate with other departments to share and disseminate data in a controlled and documented manner.
  • Develop web-based data visualization dashboards using python and R frameworks.
  • Use and modify data analysis pipelines using nextflow and WDL.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?